Tag: UNITY Biotechnology Inc. [NASDAQ: UBX]

Business

The Phase 1 Safety Study of UBX1325 in Patients with Advanced Disease from DME was a Success, UNITY Biotechnology, Inc. [NASDAQ: UBX] Reports

Ophthalmologic diseases, including diabetic macular edema, age-related neurologic conditions, and age-related macular degeneration, are prevalent today. These and other similar ones cause considerable economic, personal, and societal burdens for victims and their extended families. That said, UNITY Biotechnology, Inc. [NASDAQ: UBX] has embraced the responsibility of developing therapeutics to slow, […]